Latest News
Shionogi & Co., Ltd.
- Shionogi to Present New Real-World Data Advancing the Understanding of ALS at the 2026 Annual NEALS Meeting
- Shionogi & Co., Ltd. Estimates – TSE:4507
- IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections
- Shionogi to acquire IntraBio for $2B
- Japan's Shionogi continues rare disease expansion with acquisition of IntraBio for $2 B
- Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition
- Roundup: Shionogi Inc. Acquires IntraBio, Gate Bioscience extends Collaboration with Eli Lilly, Alector Enters Global License Agreement with Genentech
- Celaid Therapeutics secures Series B funding from Shionogi and Teikoku - Vietnam Investment Review
- Cleary, Kirkland and DLA Piper Lead on Shionogi’s $2B IntraBio Acquisition
- Japan's Shionogi to Buy U.S. Bioventure for 2 B. Dollars
- Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc.
- Shionogi & Co. to Acquire IntraBio for $2 Billion
Headlines from the last 30 days, linking to the original publishers. See all market news →